INO - Inovio Pharmaceuticals, Inc. Последние... | Finranks

20.10.2026

INOVIO Announces Favorable Judgment in Litigation with VGXI, Inc. and GeneOne Life Science

PLYMOUTH MEETING, Pa., Oct. 20, 2026 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it secured a judgment in its favor, in the amount of $80,416,101, on all claims it filed against defendants VGXI, Inc. ("VGXI") and GeneOne Life Science, Inc. ("GeneOne") in the case captioned INOVIO Pharmaceuticals, Inc. v.

14.09.2026

Bet on 4 Top-Ranked Stocks With Rising P/E

Tap four stocks with increasing P/E ratios to try out an out-of-the-box investment approach.

11.09.2026

Inovio Pharmaceuticals, Inc. (INO) Presents at H.C. Wainwright 28th Annual Global Investment Conference Prepared Remarks Transcript

11.09.2026

Inovio Nears FDA Decision on INO-3107 as Oct. 30 PDUFA Date Looms

Inovio Pharmaceuticals NASDAQ: INO said its biologics license application for INO-3107, an investigational DNA medicine for recurrent respiratory papillomatosis, or RRP, remains under U.S. Food and Drug Administration review, with a target action date of Oct. 30.

10.09.2026

Inovio Pharmaceuticals Nears Oct. 30 FDA Decision for INO-3107 in RRP

Inovio Pharmaceuticals NASDAQ: INO is approaching an October 30 PDUFA date for INO-3107, its lead DNA medicine candidate for recurrent respiratory papillomatosis, or RRP, President and CEO Jacky Shea said during a Cantor Fitzgerald fireside chat.

09.09.2026

Inovio Pharmaceuticals, Inc. (INO) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript

03.09.2026

Bet on 5 Top-Ranked Stocks With Rising P/E

Tap these five stocks - CURI, INO, GDS, NMG and CCOI - with increasing P/E ratios to try out an out-of-the-box approach.

Видео

No Data

There is no data to display

Повышения / Понижения рейтинга

Тикер	Фирма	Изменение рейтинга	Целевая цена	Дата
INO	Jefferies	Buy	undefined >> $3	August 13th 2026

Пресс-релизы

20.10.2026

Inovio Pharmaceuticals, Inc. (INO)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Контакты

Мы в соцсетях

Inovio Pharmaceuticals, Inc. (INO)

INOVIO Announces Favorable Judgment in Litigation with VGXI, Inc. and GeneOne Life Science

Bet on 4 Top-Ranked Stocks With Rising P/E

Inovio Pharmaceuticals, Inc. (INO) Presents at H.C. Wainwright 28th Annual Global Investment Conference Prepared Remarks Transcript

Inovio Nears FDA Decision on INO-3107 as Oct. 30 PDUFA Date Looms

Inovio Pharmaceuticals Nears Oct. 30 FDA Decision for INO-3107 in RRP

Inovio Pharmaceuticals, Inc. (INO) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript

Bet on 5 Top-Ranked Stocks With Rising P/E

Видео

No Data

Повышения / Понижения рейтинга

Пресс-релизы

INOVIO Announces Favorable Judgment in Litigation with VGXI, Inc. and GeneOne Life Science

INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Search stocks

Inovio Pharmaceuticals, Inc. (INO)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Контакты

Мы в соцсетях

Inovio Pharmaceuticals, Inc. (INO)

INOVIO Announces Favorable Judgment in Litigation with VGXI, Inc. and GeneOne Life Science

Bet on 4 Top-Ranked Stocks With Rising P/E

Inovio Pharmaceuticals, Inc. (INO) Presents at H.C. Wainwright 28th Annual Global Investment Conference Prepared Remarks Transcript

Inovio Nears FDA Decision on INO-3107 as Oct. 30 PDUFA Date Looms

Inovio Pharmaceuticals Nears Oct. 30 FDA Decision for INO-3107 in RRP

Inovio Pharmaceuticals, Inc. (INO) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript

Bet on 5 Top-Ranked Stocks With Rising P/E

Видео

No Data

Повышения / Понижения рейтинга

Пресс-релизы

INOVIO Announces Favorable Judgment in Litigation with VGXI, Inc. and GeneOne Life Science

INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights